ArticleJournal of clinical medicine2021
Hemoadsorption in 'Liver Indication'-Analysis of 109 Patients' Data from the CytoSorb International Registry.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Use of intraoperative haemoadsorption in patients undergoing heart transplantation: a proof-of-concept randomized trial.ESC heart failure · 2024Trial
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Feasibility and Safety of Cytosorb Application in Patients With Acute Liver Failure.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- The international, prospective CytOSorbJournal of intensive medicine · 2025Article
- Article
- From critical care to organ preservation: the potential role of hemadsorption in transplantation-a narrative review.Hepatobiliary surgery and nutrition · 2025Review
- Reply to Riva et al. Comment on "Gaspari et al. Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2025Article
- Comment on Gaspari et al. Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2025Article
- Extracorporeal liver support techniques: a comparison.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2024Article
- Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure.Scientific reports · 2024Observational
- Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2024Article
- Hemoadsorption in Organ Preservation and Transplantation: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review.Biomedicines · 2023Review
- Liver-Support Therapies in Critical Illness-A Comparative Analysis of Procedural Characteristics and Safety.Journal of clinical medicine · 2023Article
- Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report.Journal of medical case reports · 2023Article
- Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions.World journal of clinical cases · 2023Review
- Artificial Liver Support with CytoSorb and MARS in Liver Failure: A Retrospective Propensity Matched Analysis.Journal of clinical medicine · 2023Article
- The Influence of Interdisciplinary Work towards Advancing Knowledge on Human Liver Physiology.Cells · 2022Review
- Hemoperfusion in the intensive care unit.Intensive care medicine · 2022Review
- Immunomodulation by Hemoadsorption-Changes in Hepatic Biotransformation Capacity in Sepsis and Septic Shock: A Prospective Study.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 6 countries.
Funding
Abstract
backgroundOur aim is to report the results of the 'liver indication' subset of patients in the CytoSorb International Registry.
methodsStructured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians.
resultsUntil January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24-72 h) in total. Serum bilirubin levels reduced significantly to -4.6 (95% CI: -6.329 to -2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event.
conclusionsWe report the largest case series on hemoadsorption for 'liver indication' from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.